Last reviewed · How we verify

Enterobacter Osteomyelitis — Treatment Landscape & Competitive Intelligence

Enterobacter Osteomyelitis (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Enterobacter Osteomyelitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Cipro ciprofloxacin Bayer AG Fluoroquinolone antibiotic DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A 1987-10-22
Fortaz CEFTAZIDIME Pai Holdings Pharm ceftazidime 1985-01-01
Rocephin ceftriaxone Generic (originally Roche) Cephalosporin antibiotic (third-generation) Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A 1984-12-21
Vantobra Tobramycin Sulfate Pfizer tobramycin Taste receptor type 2 member 20 1974-01-01
Tobi tobramycin Novartis Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)
Ceftriaxon Ceftriaxon Centre Hospitalier Universitaire Vaudois Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A
Ceftazidim Ceftazidim Tel-Aviv Sourasky Medical Center Penicillin-binding protein 1A, Penicillin-binding protein 1B, Peptidoglycan synthase FtsI
Ofloxacine Ofloxacine Assistance Publique - Hôpitaux de Paris Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1
Ciprofloxacine Ciprofloxacine Poitiers University Hospital DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A
Nebcin Nebcin University Hospital, Lille Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 3 drugs in Enterobacter Osteomyelitis
  2. Pai Holdings Pharm · 2 drugs in Enterobacter Osteomyelitis
  3. Bayer AG · 1 drug in Enterobacter Osteomyelitis
  4. Centre Hospitalier Universitaire Vaudois · 1 drug in Enterobacter Osteomyelitis
  5. Generic (originally Roche) · 1 drug in Enterobacter Osteomyelitis
  6. Novartis · 1 drug in Enterobacter Osteomyelitis
  7. Pfizer · 1 drug in Enterobacter Osteomyelitis
  8. Poitiers University Hospital · 1 drug in Enterobacter Osteomyelitis
  9. Tel-Aviv Sourasky Medical Center · 1 drug in Enterobacter Osteomyelitis
  10. University Hospital, Lille · 1 drug in Enterobacter Osteomyelitis
  11. Assistance Publique - Hôpitaux de Paris · 1 drug in Enterobacter Osteomyelitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Enterobacter Osteomyelitis:

Cite this brief

Drug Landscape (2026). Enterobacter Osteomyelitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/enterobacter-osteomyelitis. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing